Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients

Hepatocellular Carcinoma in Tyrosinemia Type 1 Without Clear Increase of AFP

“…3,[5][6][7] In other diseases with a high risk of developing HCC (eg, hepatitis B and C), up to 44% of patients diagnosed with HCC show no clear increase in AFP levels. 8,9 Until now, all reported HT1 patients with proven HCC had exhibited a well-defined rise in AFP levels and a clear lesion at imaging. 1,5,6 Therefore, AFP in HTI has always been considered a reliable marker for HCC development.…”

Current biomarkers for hepatocellular carcinoma: Surveillance, diagnosis and prediction of prognosis

“…Using different cut-off-values, sensitivity for HCC ranged from 46% to 73% with a specificity of 87% to 95% [32,34,35] . The largest study on the role of the serine protease inhibitor SCCA included 961 patients and resulted in a sensitivity of 42% at specificity of 83% using a cut-off of 3.8 ng/mL [32,36] . Seven well-designed studies on the diagnostic performance of osteopontin, an integrin-binding glycophosphoprotein, were published and recently summarized in a meta-analysis [24] .…”

SERPINB3 modulates TGF-β expression in chronic liver disease

“…19 Serpins function via an exposed reactive site loop (RSL) of about 20 amino acids and inhibit irreversibly proteinases through a suicide substrate inhibition mechanism. 19 SCCA isoforms have been found overexpressed in epithelial tumors, 20 primary liver cancer, [21][22][23] and chronically damaged hepatocytes. [24][25][26] The aim of this study was to assess the potential correlation between TGF-b1 and SERPINB3 in chronically damaged human liver tissue and to determine their relationship using in vitro models of cultured cells transfected with vectors expressing SERPINB3.…”